Aryl fructose-1,6-bisphosphatase inhibitors

Details Aryl fructose-1,6-bisphosphatase inhibitors Aryl fructose-1,6-bisphosphatase inhibitors

2008-05-13

2008-05-13

Rao, Deepak (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Phosphorus containing other than solely as part of an...

C546S022000

Reexamination Certificate

active

11043859

ABSTRACT:
Novel FBPase inhibitors of the formula Iare useful in the treatment of diabetes and other conditions associated with elevated blood glucose.

REFERENCES:
patent: 2674599 (1954-04-01), Suter
patent: 3524846 (1970-08-01), Moffat et al.
patent: 4640701 (1987-02-01), Diel et al.
patent: 4746653 (1988-05-01), Hutchison et al.
patent: 4968790 (1990-11-01), DeVries et al.
patent: 5045557 (1991-09-01), Buss et al.
patent: 5157027 (1992-10-01), Biller et al.
patent: 5278153 (1994-01-01), Biller
patent: 5658889 (1997-08-01), Gruber et al.
patent: 5728704 (1998-03-01), Mylari et al.
patent: 6054587 (2000-04-01), Reddy et al.
patent: 6110903 (2000-08-01), Kasibhatla et al.
patent: 6284748 (2001-09-01), Dang et al.
patent: 6294672 (2001-09-01), Reddy et al.
patent: 6312662 (2001-11-01), Erion et al.
patent: 6399782 (2002-06-01), Kasibhatla et al.
patent: 6489476 (2002-12-01), Dang et al.
patent: 6756360 (2004-06-01), Erion et al.
patent: 6919322 (2005-07-01), Bookser et al.
patent: 6965033 (2005-11-01), Jiang et al.
patent: 6967193 (2005-11-01), Dang et al.
patent: 2003/0073728 (2003-04-01), van Poelje et al.
patent: 2004/0058892 (2004-03-01), Dang et al.
patent: 2004/0167178 (2004-08-01), Erion et al.
patent: 2005/0004077 (2005-01-01), Jiang et al.
patent: 19843383 (2000-03-01), None
patent: 243173 (1987-10-01), None
patent: 0354322 (1989-06-01), None
patent: 0427799 (1994-11-01), None
patent: 0632048 (1995-01-01), None
patent: WO 90/08155 (1990-07-01), None
patent: WO 90/10636 (1990-09-01), None
patent: WO 91/19721 (1991-12-01), None
patent: WO 95/07920 (1995-03-01), None
patent: WO 98/39342 (1998-09-01), None
patent: WO 98/39343 (1998-09-01), None
patent: WO 98/39344 (1998-09-01), None
patent: WO 99/45016 (1999-09-01), None
patent: WO 99/47549 (1999-09-01), None
patent: WO 00/14095 (2000-03-01), None
patent: WO 00/27401 (2000-05-01), None
patent: WO 00/38666 (2000-07-01), None
patent: WO 00/52015 (2000-09-01), None
patent: WO 01/47935 (2001-07-01), None
patent: WO 01/52825 (2001-07-01), None
patent: WO 01/66553 (2001-09-01), None
patent: WO 01/89457 (2001-11-01), None
patent: WO 02/03978 (2002-01-01), None
patent: WO 2006/023515 (2006-03-01), None
Jing et al., Caplus Abstract 127:205633, 1997.
Matczak-Jon et al., Caplus Abstract 102:124498, 1985.
Toraya et al., Caplus Abstract 120:292682, 1994.
Silverman, Prodrugs and Drug Delivery Systems, The Organic Chemistry of Drug Design and Drug Action, pp. 352-400, 1992.
Bundgaard, Design of Prodrugs: Introduction, p. 1, 1985.
Alexander, et al. “Preparation of 9-(2-Phosphonomethoxyethyl)adenine Esters as Potential Prodrugs,”Collect. Czech Chem. Commun., 1994, pp. 1853-1869, vol. 59.
Athmani, et al. “Azoles, Part 9. Synthesis of Derivatives of Thieno[2,3-d]thiazole, 4H-Pyrrolo-[2.3-d]thiazole, 2H-Pyrazolo[3,4-d]thiazole from Thiazolidine-2,4-dione.”J. Chem Soc. Perkin Trans.1, 1992, pp. 973-977.
Barluenga, et al. “Substituted Organolithium Compounds. New Reagents for Synthesis,”J. Org. Chem., 1979, pp. 4798-4801, vol. 44, No. 26.
Benzaria, et al. “Synthesis in vitro Antiviral Evaluation, and Stability Studies of Bis(S-acyl-2-thioethyl) Ester Derivatives of 9-[2-(Phosphonomethoxy)ethyl]adenine (PMEA) as Potential PMEA Prodrugs with improved Oral Bioavailability,”J. Med. Chem., 1996, pp. 4958-4965, vol. 39.
Bhongle, et al. “Expedient and High-Yield Synthesis of Alkylphosphonyl Dichlorides Under Mild, Neutral Conditions: Reaction of Bis(Trimethylsilyl)Alkyl Phosphonates with Oxalyl Chloride/Dimethylformamide,”Synth. Commun., 1987, pp. 1071-1076, vol. 17, No. 9.
Brinton, et al. “Characterization of Murine CaraparuBunyavirusLiver infection and Immunomodulator-Mediated Antiviral Protection,”Antiviral Res., 1992, pp. 155-171, vol. 20.
Campagne, et al. “Synthesis of Mixed Phosphonate Diester Analogues of Dipeptides using BOP or PyBOP Reagents,”Tetrahedron Lett., 1993, pp. 6743-6744, vol. 34.
Campbell, et al. “The Synthesis of Phosphonate Esters, an Extension of the Mitsunobu Reaction,”J. Org. Chem., 1992, pp. 6331-6335, vol. 57.
Canas, et al. “Regioselective Ring Opening of Chiral Epoxyalcohols by Primary Amines,”Tetrahedron Lett., 1991, pp. 6931-6934, vol. 32.
Casara, et al. “Synthesis of Acid Stable 5′-O-Fluoromethyl Phosphonates of Nucleosides. Evaluation as Inhibitors of Reverse Transcriptase,”Bioorg. Med. Chem. Lett., 1992, pp. 145-148, vol. 2.
Claus, et al. “Mechanism of the Acute Action of Insulin on Hepatic Gluconeogenesis,”Mechanisms of Insulin Action, 1992, pp. 305-321, Elsevier Science.
Commercon, et al. “Diastereoselective Chlorocyclofunctionalization of N-allylic Trichloroacetamides: Synthesis of an Analogue and Potential Precurser of RP49532,”Tetrahedron Lett., 1990, pp. 3871-3874, vol. 31.
Corey, et al. “Enantioselective and Practical Synthesis of R-and S-Fluoxetines,”Tetrahedron Lett., 1989, pp. 5207-5210, vol. 30.
Curran, “Thermolysis of Bis[2—[(trimethylsilyl)oxy]prop-2-yl] fuxoran (TOP-furoxan). The First Practical Method for Intermolecular Cycloaddition of an in Situ Nitrile Oxide with 1,2-Di and Trisubstituted Olefins.”J. Am. Chem. Soc., 1985, pp. 6023-6028, vol. 107.
De Lombaert, et al. “N-Phosphonomethyl Dipeptides and Their Phosphonate Prodrugs, a New Generation of Neutral Endopeptidase (NEP, EC 3.4.24.11) Inhibitors,”J. Med. Chem., 1994, pp. 498-511, vol. 37.
Dickson, et al. “Orally Active Squalene Synthase Inhibitors: Bis(acyloxy) Prodrugs of the α-Phosphonosulfonic Acid Moiety,”J. Med. Chem., 1996, pp. 661-664, vol. 39.
Egron, et al. “Synthesis and Anti-HIV Activity of Some S-Acyl-2-Thioethyl (SATE) Phosphoramidate Derivatives of 3′-Azido-2′,3′-Dideoxythymidine,”Nucleosides and Nucleotides, 1999, pp. 981-982, vol. 18.
Elhaddadi, et al. “A Convenient Synthesis of Alkyl and Dialkyl 1-Benzyloxyamino Alkyl Phosphonates and Phosphinates,”Phosphorous, Sulfur, and Silicon, 1990, pp. 143-150, vol. 54, Nos. 1-4.
Farquhar, et al. “Biologically Reversible Phosphate-Protective Groups,”J. Pham Sci., 1983, pp. 324-325, vol. 72.
Ferres, H. “Pro-Drugs of β-Lactam Antibiotics,”Drugs of Today, 1983, pp. 499-538, vol. 19.
Folsom, et al. “Relation of Cartoid artery Wall Thickness to Diabetes Mellitus, Fasting Glucose and Insulin, Body Size, and Physical Activity,”Stroke, 1994, pp. 66-73, vol. 25.
Freed, et al. “Evidence for Acyloxymethyl Esters of Pyrimidine 5′-Deoxyribonucleotides as Extracellular Sources of Active 5′-Deoxyribonucleotides in Cultured Cell,”Biochem. Pharmacol., 1989, pp. 3193-3198, vol. 38.
Haddad, et al. “Stereocontrolled Reductive Amination of 3-Hydroxy Ketones,”Tetrahedron Lett., 1997, pp. 5981-5984, vol. 38.
Hoffmann, M. “A Simple, Efficient Synthesis of Dibenzyl and Di-p-nitroben 1-Hydroxyalkanephosphonates,”Synthesis, 1988, pp. 62-64.
Hori, et al. “Palladium (II)-Catalyzed Asymmetric 1,3-Dipolar Cycloaddition of Nitrones to 3-Alkenoyl-1,3-oxazodilin2-ones,”J. Org. Chem., 1999, pp. 5017-5023, vol. 64.
Howard, G. et al. “Insulin Sensitivity and Atherosclerosis,”Circulation, 1996, pp. 1809-1817, vol. 93.
Iyer, et al. “Synthesis of Acyloxyalkyl Acylphosphonates as Potential Prodrugs of the Antiviral, Trisodium Phosphonoformate (Foscarnet Sodium),”Tetrahedron Lett., 1989, pp. 7141-7144, vol. 30.
Khamnei, et al. “Neighboring Group Catalysis in the Design of Nucleotide Prodrugs,” J. Med. Chem., 1996, pp. 4109-4115, vol. 39.
Koizumi, et al. “Complete Regio-and Stereospecificity in the Lewis Acid Catalyzed Diels-Alder Reactions of (Z) 2-Methoxy-1(phenolthio)-1,3-butadienes. Conversion of the CS Configuration of an Adduct to the CC Configuration at the Allylic Position by a [2,3] Sigmatropic Rearrangement,”J. Org. Chem, 1982, pp. 4005-4008, vol. 47.
Martin, et al. “Synt

Affiliated with

Also associated with

Rating

Aryl fructose-1,6-bisphosphatase inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Aryl fructose-1,6-bisphosphatase inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Aryl fructose-1,6-bisphosphatase inhibitors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3946503